Literature DB >> 32789589

Optimizing Bariatric Surgery outcomes: the impact of preoperative elevated hemoglobin A1c levels on composite perioperative outcome measures.

Alexander Hart1, Paolo Goffredo2, Rory Carroll2, Ryan Lehmann2, Peter Nau2, Jessica Smith2, Sajida Ahad2, Wei Bao3, Imran Hassan4.   

Abstract

INTRODUCTION: The use of bariatric surgery in the management of obesity and its related morbidity has significantly increased in the US over the past decade. There is a lack of data on the impact of optimal preoperative glycemic control on the morbidity and mortality following bariatric surgery. The aim of this study was to analyze the impact of hemoglobin (Hb) A1c > 7 on outcomes among patients undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG).
METHODS: Data were extracted from the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (2017) and limited to patients undergoing an elective laparoscopic RYGB or SG. Multivariable logistic regression was conducted to adjust for other preoperative variables.
RESULTS: A total number of 31,060 (69.3%) patients underwent SG, while 13,754 (30.7%) received RYGB. Patients who were older, male, non-Hispanic, smokers, and those with a higher American Society of Anesthesiologist Classification (ASA) score were more likely to have elevated HbA1c levels. Compared to individuals with normal HbA1c levels, patients with elevated levels had no significant difference in mortality (p = 0.902) but did have a difference in composite morbidity and mortality (p < 0.001). On multivariable analysis, elevated HbA1c, older age, increasing body mass index (BMI), elevated creatinine, longer operations, African American race, receiving RYGB, and having a trainee as surgical assistant were found to increase the odds of having an adverse outcome. No significant difference was found within smoking status, sex, ASA Classification, robotic vs laparoscopic, or if a second attending surgeon was assisting.
CONCLUSIONS: HbA1c levels and presence of trainees in the OR are modifiable preoperative risk factors for adverse events following bariatric surgery. Improving preoperative glycemic control may be an effective and achievable quality improvement measure.

Entities:  

Keywords:  Bariatric surgery; Glycemic control; HbA1c; MBSAQIP; Outcomes

Mesh:

Substances:

Year:  2020        PMID: 32789589      PMCID: PMC8823948          DOI: 10.1007/s00464-020-07887-9

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


Bariatric surgery has become increasingly utilized over the past decade as a safe and efficacious way to treat morbid obesity and related conditions [1-4]. The indications for bariatric procedures include a Body Mass Index (BMI) > 40 kg/m2, or having a BMI > 35 kg/m2 with an obesity-related comorbidity, including diabetes. Overall, ~ 25% of morbidly obese patients will develop diabetes compared to 8.9% of the general population [5]. As a consequence, the obese subpopulation has an increased prevalence of elevated hemoglobin (Hb) A1c values [6-16]. Higher preoperative HbA1c levels are known to increase postoperative morbidity in a variety of surgical patient cohorts [17, 18]. Aminian et al. developed a validated risk calculator tool utilizing a cohort of 659 patients from a single institution, where controlled preoperative HbA1c was found to be a significant predictor of postoperative glycemic control [18]. This association between preoperative HbA1c and postoperative glycemic control was also noted in a retrospective chart review of 468 bariatric surgery patient by Perna et al. [19] This study found elevated preoperative HbA1c to be associated with lower rates of diabetic remissions and weight loss. However, there is a scarcity of data on the impact of achieving good preoperative glycemic control on postoperative outcomes following bariatric surgery. The current study aimed to analyze the association between preoperative HbA1c levels and 30 day postoperative complications following bariatric surgery utilizing the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Database. We hypothesized that elevated preoperative HbA1c levels (> 7) prior to bariatric surgery would be associated with worse postoperative outcomes.

Materials and methods

Data source

The Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program Participant Use Data File (MBSAQIP PUF) was analyzed for the year 2017. This data file is Health Insurance Portability and Accountability Act Compliant covering 780 accredited bariatric surgery programs in the United States and Canada, and accounts for 94% of all bariatric surgeries in these countries. Data entry is performed by trained metabolic and bariatric surgical clinical reviewers via patient medical record review [20]. This study included all patients with documented preoperative HbA1c levels who underwent a standard laparoscopic or robotic Sleeve Gastrectomy (SG) or Roux-en-Y Bypass (RYGB) (Current Procedural Terminology codes 43775, 43644, and 43645). Sixty-six percent of the patients did not have a recorded preoperative HbA1c level and were thus excluded from the analyses. Patients who had emergent, revision, open, or converted to open surgeries were excluded. Patients were also excluded if they had a history of previous midgut surgery or if they had secondary Current Procedural Terminology (CPT) codes associated with the treatment of comorbid conditions which would affect postoperative outcomes. Hemoglobin A1c levels > 7 were defined as elevated. All patients had A1c levels checked prior to the surgical intervention.

Outcomes and statistical analysis

Complication data was collected from the MBSAQIP. This study utilizes a composite Death and Serious Morbidity outcome, which included 30-day mortality, ventilator requirement after 48 h, an unplanned intubation, pneumonia, superficial surgical site infection, deep surgical site infection, organ space surgical site infection, pulmonary embolism, a reintervention within 30 days, myocardial infarction, sepsis, septic shock, cerebrovascular accident, cardiac arrest requiring cardio pulmonary resuscitation, progressive renal insufficiency, or vein thrombosis requiring treatment [21-23]. The composite outcome represented the summation of the counts of all listed adverse events. This decision was driven by the relatively low number of each individual complication. Univariately continuous variables were compared using 2-sided t-tests, and categorical variables were compared using chi-squared analysis. Multivariate logistic regression was conducted utilizing the composite outcome member. All tests were two sided and a p value < 0.05 was set for significance. P values with > 4 decimals were rounded up to < 0.001. This work was deemed to be IRB exempt and did not qualify as human subject research. Analyses were conducted in SAS version 9.4 (SAS Institute, Cary, NC) 8.3.5.

Results

A total of 44,814 patients met inclusion criteria: 69.3% patients underwent SG, while 30.7% had RYGB. The cohort included primarily females (77.6%) and Caucasians (72.6%). Mean BMI was 45.6 kg/m2. The mean age in the elevated HbA1c cohort was 47.7 years as compared to 43.6 years in the normal level population (Table 1). Gender differed significantly between the two groups with the elevated group being having a higher proportion of females compared to the normal group (71.1% vs 79.6%, p < 0.001). Also, positive smoking status was significantly higher in the elevated HbA1c group being 8.7% of the cohort versus 8.0% in the normal group (p = 0.032). Additionally, mean BMI was lower in the elevated HbA1c group at (45.0 kg/m2 vs 45.8 kg/m2, p < 0.001). Patients in the elevated HbA1c group underwent SG less frequently than the normal cohort (61.7% vs 71.7%, p < 0.001). The elevated HbA1c group had a higher proportion of patients with ASA ≥ 3 as compared to the normal HbA1c group (85.8% vs 78.2%, p < 0.001).
Table 1

Preoperative univariate comparison between patients with elevated and non-elevated HbA1c levels

VariablesA1c > 7N = 10,641, %A1c ≤ 7N = 34,173, %p value
Female gender71.179.6< .001
Race< .001
 Black18.117.2
 Other8.310.6
 White73.772.3
Age (mean ± SD)47.7 ± 11.443.6 ± 11.9< .001
BMI (mean ± SD)45.0 ± 7.945.8 ± 7.9< .001
ASA Category ≥ 385.878.2< .001
Smoker status8.78.00.032
Hematocrit (mean ± SD)41.0 ± 4.140.8 ± 3.90.004
Creatinine (mean ± SD)0.9 ± 0.80.8 ± 0.5< .001
Surgery Performed< .001
 Roux-en-Y Gastric Bypass38.328.3
 Sleeve Gastrectomy61.771.7
First Assist level< .001
 None13.212.8
 PA/NP/RN43.736.7
 Resident (PGY1-5+)16.819.4
 MIS Fellow9.311.3
 Attending-Other3.74.4
 Attending-Bariatric Surgeon13.415.5
Approach< .001
 Robotic-Assisted7.58.4
 Conventional Laparoscopic87.489.2
 Laparoscopic assisted5.12.4
Operative time, min (mean ± SD)87.8 ± 49.083.2 ± 46.4< .001
Drain Placement15.517.3< .001
Preoperative univariate comparison between patients with elevated and non-elevated HbA1c levels In univariate analysis, postoperative outcomes of patients with elevated HbA1c levels were compared to those of the normal HbA1c group (Table 2). Although there was no difference in mortality, significantly higher rates of composite morbidity and mortality were observed in the elevated HbA1c group (p < 0.001).
Table 2

Postoperative outcomes by elevated and non-elevated HbA1c levels

OutcomeAlc > 7N = 10,641, %A1c ≤ 7N = 34,173, %p value
Composite morbidity/mortality2.82.1< .001
 30-day mortality0.10.10.902
 On Ventilator > 48 h000.264
Unplanned Intubation0.30.1< .001
 Intervention within 30 days1.21.10.384
Pneumonia000.011
 Pulmonary embolism0.10.10.845
 Myocardial infarction000.361
 Cerebrovascular accident0.100.295
 Cardiac arrest requiring CPR0.10.10.150
 progressive renal insufficiency0.10.10.376
 Vein thrombosis requiring treatment0.10.20.561
Superficial surgical site infection0.60.4< 0.001
 Deep surgical site infection0.100.213
 Organ space surgical site infection0.30.20.3534
Post-op Pneumonia0.30.1< 0.001
Post-op septic shock0.10.10.026
Post-op Sepsis0.20.10.001
Postoperative outcomes by elevated and non-elevated HbA1c levels On multivariable analysis, elevated HbA1c was found to have significantly increased odds of having an adverse postoperative outcome (odds ratio = 1.2, 95% CI 1.03–1.37). Older age, BMI, elevated creatinine, longer operations, African American race, and undergoing a RYGB were all independently associated with higher postoperative morbidity rates (all p < 0.001). As compared to having a nurse practitioner or physician assistant as lead assistant, there was no increased rates of complications when the case was performed by two attending physicians. However, procedures for which there was no assistant, a resident, or a fellow as the lead assist all had significant increased odds ratios of 1.4 (95% CI 1.13–1.68), 1.3 (95% CI 1.06–1.52), and 1.4 (95% CI 1.10–1.66), respectively (Fig. 1). In a subset analysis comparing non-trainee assistants vs residents and fellows, the former group had a significantly lower reoperation rate (1.0% vs 1.4%, p = 0.030) and decreased operating time (75 ± 43 vs 102 ± 51 minutes, p < 0.001). No significant difference was found within smoking status, sex, ASA Classification, or robotic vs laparoscopic surgical approach.
Fig. 1

Forest plot depicts the multivariate logistic regression with the composite morbidity and mortality outcome. Values on the right are reported as the odds ratio with the respective 95% confidence interval in parenthesis. Significant results are represented by bolding of the odds ratio and confidenc interval

Forest plot depicts the multivariate logistic regression with the composite morbidity and mortality outcome. Values on the right are reported as the odds ratio with the respective 95% confidence interval in parenthesis. Significant results are represented by bolding of the odds ratio and confidenc interval

Discussion

This study utilized a large nationally representative database to evaluate the impact of HbA1c on short-term outcomes after bariatric surgery. Our data suggest a positive association between elevated HbA1c levels and the odds of developing postoperative complications. Moreover, the presence of trainees in the OR and undergoing RYGB were independently associated with adverse outcomes. Our findings support the hypothesis that elevated HbA1c levels are associated with adverse outcomes following bariatric surgery. This observation is in contrast with the conclusion of Rawlins et al. Those authors published a retrospective study of 342 patients undergoing a RYGB and found that elevated preoperative HbA1c did not increase complication rates [24]. This difference may be explained by two main reasons: 1. the sample size was much smaller so the study had lower statistical power; 2. all 342 patients were treated with medications for glycemic control, which could lessen the effects of elevated HbA1c levels. Other fields have also identified preoperative HbA1c as a risk factor for postoperative morbidity. In posterior thoracic and lumbar spinal surgery, Hikata et al. found elevated HbA1c to be associated with increased rates of surgical site infection [25]. Gustafsson et al., in the field of colorectal surgery, found among 120 prospectively followed patients that elevated preoperative HbA1c was predictive of poor postoperative glycemic control and increased postoperative complication rates [26]. Additionally, Underwood et al. reported that elevated HbA1c was associated with poor surgical outcomes, such as longer length of stay, following non cardiac procedures on diabetics [27]. Moreover, following coronary artery bypass grafting, an elevated HbA1c level was identified to significantly increase the odds of mortality, myocardial infarction, and deep sternal wound infection [28]. Interestingly, being in an elevated ASA category did not increase the risk of postoperative complications in this study. Elevated HbA1c is included in calculating ASA category, indicating that this measure alone could be a more valuable indicator of postoperative risk compared to the composite preoperative measure. Therefore, given the elective setting of bariatric surgery, efforts should be made to control preoperative hyperglycemia to decrease the rate of short-term complications. It was found that having no assist, a surgical resident, or a minimally invasive surgical fellow was associated with worse outcomes, as compared to having any attending surgeon as the lead assist. This is consistent with a study utilizing MBSAQIP by Bonner et al., which showed that having a trainee surgeon as assistant was significantly associated with adverse postoperative outcomes in bariatric surgery [29]. In addition, Aminian et al. found in the standard NSQIP that fellows involved with Roux-en-Y bypass had increased odds of surgical complications and reoperation as compared to surgeries with no trainees involved [30]. Hsu et al. in a single institution study found similar results; lower assistant training levels were significantly associated with longer operative times and increased blood loss, as well as higher intraoperative complication and re-admission rates, intensive care unit admissions, or length of stay [31]. On the other hand, the results published by Oliak et al. and others showed that fellowship trained bariatric surgeons had shorter intraoperative time, lower rates of major complications, and decreased mortality [32-34]. These results indicate that further work should be done to implement new teaching models.in the training of bariatric surgeons to balance the complications of future versus current patients. This study had several limitations, including those inherent to large datasets (ie coding errors). Although a composite outcome may limit the clinical interpretation of the results, this score was utilized for two primary reasons: (1) limited sample size of each individual outcome; and (2) wide range of systemic effects of elevated HbA1c levels. The goal was to capture this effect by combining a large variety of outcomes. However, due to differential frequencies of some adverse outcomes, there could be uneven representation of specific complications in the composite morbidity measure. Additionally, two thirds of the initial cohort were excluded due to missing HbA1c levels, which could have potentially introduced a bias in our analyses. This should be at least in part mitigated by the large sample size and the generally nationally representative nature of the MBSASQIP dataset. Another limitation was the ability to only measure information available in the database. Variables not included in the data set such as socio-economic or insurance status, current or previous medical management of diabetes, or center volume may have effects on surgical outcomes. Lastly, the MBSAQIP PUF only includes 30-day outcomes, therefore long-term outcomes could not be studied. In conclusion, the current study identified high HbA1c levels and presence of trainees in the OR as potentially modifiable preoperative risk factors for adverse events following bariatric surgery in a nationally representative cohort. Improving preoperative glycemic control prior to bariatric surgery may be a feasible goal, which could represent an important quality improvement measure. Presence of trainees in the operating room, on the other hand, poses a more difficult challenge to overcome. Further studies focusing on surgical education would be warranted to implement safe and effective training in the field of bariatric surgery.
  1 in total

1.  Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity.

Authors:  Anita P Courcoulas; Nicholas J Christian; Steven H Belle; Paul D Berk; David R Flum; Luis Garcia; Mary Horlick; Melissa A Kalarchian; Wendy C King; James E Mitchell; Emma J Patterson; John R Pender; Alfons Pomp; Walter J Pories; Richard C Thirlby; Susan Z Yanovski; Bruce M Wolfe
Journal:  JAMA       Date:  2013-12-11       Impact factor: 56.272

  1 in total
  1 in total

1.  Elevated hemoglobin A1c level and bariatric surgery complications.

Authors:  Ugoeze Nwokedi; Mahnoor Zia; Jiaqiong Xu; Archana R Sadhu; Flavio E Baio; Bita S Kash; Vadim Sherman; Nabil Tariq
Journal:  Surg Endosc       Date:  2022-01-24       Impact factor: 3.453

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.